E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Renal Transplant Rejection - chronic |
|
E.1.1.1 | Medical condition in easily understood language |
Kidney transplant rejection - chronic |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10023439 |
E.1.2 | Term | Kidney transplant rejection |
E.1.2 | System Organ Class | 10021428 - Immune system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether anti-CD20 therapy can stabilise or improve renal function and/or proteinuria in patients with C4d+, chronic (humoral) rejection in whom standard therapeutic approaches have failed.
|
|
E.2.2 | Secondary objectives of the trial |
To compare patient and graft survival between control and rituximab-treated groups
To evaluate the adverse effect profile of rituximab in this group
To correlate changes in circulating B cell numbers, anti-HLA and non-HLA Ab profiles and titre with responses to standard therapy and / or rituximab
To correlate changes in T cell responsiveness to alloantigens with responses to standard therapy and / or rituximab |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
To be included in the study the patient must have:
•A functioning kidney allograft (with estimated GFR by MDRD >20) and be >6/12 post-transplantation
•Either deteriorating allograft function as defined by linear regression of reciprocal creatinine plot. Deterioration will be defined as a negative slope over at least the preceding 3 months (with at least 6 creatinines included) with an adjusted r2 >0.35 and a p value of ≤0.05 compared to horizontal baseline. Deterioration will be confirmed by Cockcroft Gault eGFR somparisons over same period to rule out body mass as a cause of change in creatinines
OR Significant proteinuria defined as a urine protein : creatinine ratio ≥50
OR Both deteriorating function and proteinuria
•CAN, by Banff ’97 criteria, or transplant glomerulopathy on renal allograft biopsy performed within 3/12 of enrolment
•Diffuse, linear C4d deposition on at least 25% of peritubular capillary (PTC) and/or glomerular EC of renal transplant biopsy when assessed by immunoperoxidase OR >50% of PTC (alone) when assessed by immunofluorescence.
|
|
E.4 | Principal exclusion criteria |
The presence of any of the following will preclude patient inclusion
•<18 years of age
•suspicion of pregnancy confirmed by positive HCG pregnancy test
•untreated ureteric obstruction on ultrasound of allograft
•history of acute allograft rejection in preceding 3/12
•history of MI in preceding 3/12
•history of malignancy in previous 5 years (excluding tumours limited to skin)
•symptomatic IHD
•recipient of simultaneous pancreas/kidney transplant
•recipient of ABO-incompatible kidney
•recipient who underwent an HLA desensitisation procedure prior to transplantation
•evidence, on examination of renal allograft biopsy specimen, of recurrent or de-novo disease (except IgA deposition in absence of mesangial proliferation)
• evidence, on examination of renal allograft biopsy specimen, of CNI toxicity IF ACCOMPANIED by mostly supra-therapeutic CNI trough levels in the 6 month period preceding biopsy.
• doumented allergy to mouse or chimeric human/mouse proteins
• HepBsAg+, HCV Ab+ or HIV+ or HepBcAb+
• administration of lymphocyte depleting antibody within 3 months of enrolment |
|
E.5 End points |
E.5.1 | Primary end point(s) |
•Rate of deterioration in renal function, defined by slope of reciprocal creatinine plot, on samples taken in the preceding 3 months.
•Change in degree of proteinuria, where present |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Determined 3-5 months post-randomisation |
|
E.5.2 | Secondary end point(s) |
To compare patient and graft survival between control and rituximab-treated groups
To evaluate the adverse effect profile of rituximab in this group
To correlate changes in circulating B cell numbers, anti-HLA and non-HLA Ab profiles and titre with responses to standard therapy and / or rituximab
To correlate changes in T cell responsiveness to alloantigens with responses to standard therapy and / or rituximab |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoints will be determined at 3-5 months post-randomisation and at 1, 2 and 3 years post-recruitment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Standard optimal clinical care according to our unit protocol |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of last subject undergoing study |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |